GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...
With this approval, Jemperli is now indicated earlier in treatment, in combination with chemotherapy, for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Jemperli has ...
(RTTNews) - GSK plc (GSK, GSK.L) announced the FDA has approved Jemperli in combination with carboplatin and paclitaxel followed by Jemperli as a single agent for the treatment of adult patients ...
(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration expanded the use of its cancer medicine Jemperli, also known as dostarlimab, when combined with chemotherapy.
Results that may be inaccessible to you are currently showing.